business

CRISPR Therapeutics Stock Is Absurdly Cheap -- Here's Why Analysts See 437% Upside Potential

Yahoo Finance · Jun 3, 2026, 4:50 PM · Also reported by 2 other sources

Read full story on Yahoo Finance → More top stories

Also covered by

Investing.com Benchmark reiterates Halozyme stock Buy rating on long-term potential Investing.com Shake Shack stock under pressure as analysts cut ratings following lowered outlook

Aggregated and edited by the Scoop newsroom. We surface news from Yahoo Finance alongside other reporting so you can compare coverage in one place. Editorial policy · Corrections · About Scoop

CRISPR Therapeutics Stock Is Absurdly Cheap -- Here's Why Analysts See 437% Upside Potential

Also covered by

More in business